What is the prevalence of Camurati-Engelmann disease?

TL;DR: Camurati-Engelmann disease is an ultra-rare genetic bone disorder with fewer than 300 cases documented in medical literature worldwide, though the true prevalence is likely higher due to underdiagnosis. It follows an autosomal dominant inheritance pattern and typically presents with symptoms during childhood or adolescence, affecting males and females with equal frequency.

What is the estimated prevalence of Camurati-Engelmann disease?

Camurati-Engelmann disease, also known as progressive diaphyseal dysplasia, is classified as an ultra-rare condition. Because it is so uncommon, exact epidemiological data is difficult to establish. According to Orphanet and the NIH Genetic and Rare Diseases (GARD) Information Center, fewer than 300 cases have been reported in the medical literature to date. It is important to note that these numbers reflect documented clinical cases; the actual prevalence of Camurati-Engelmann disease is likely higher, as mild cases may remain asymptomatic or misdiagnosed as other bone conditions, such as chronic osteomyelitis or fibromyalgia.

What are the demographic and age-of-onset patterns for this condition?

Camurati-Engelmann disease shows no significant predilection for any specific ethnic group or geographic region, with cases reported globally. Research indicates that the condition affects males and females with equal frequency. Regarding age of onset, Camurati-Engelmann disease is primarily a pediatric-onset disorder. Most individuals begin to show clinical manifestations—such as leg pain, muscle weakness, or a waddling gait—between the ages of 3 and 10 years. While symptoms often stabilize after puberty, some patients continue to experience bone pain and mobility challenges well into adulthood.

Why is it difficult to determine the exact number of cases?

The primary challenge in mapping the true prevalence of Camurati-Engelmann disease lies in its clinical variability. Because the genetic mutation (most commonly in the TGFB1 gene) can result in a wide spectrum of severity, some individuals may have the genetic marker but experience such mild symptoms that they never seek medical intervention. Key factors complicating data collection include:

• Diagnostic overshadowing: The bone pain associated with Camurati-Engelmann disease is sometimes misattributed to growing pains or other rheumatological conditions.


• Lack of awareness: Due to the extreme rarity of Camurati-Engelmann disease, many general practitioners may never encounter a case in their entire career.


• Variable penetrance: Family members carrying the same mutation may present with vastly different degrees of skeletal involvement.

How does the DiseaseMaps community contribute to our understanding?

While formal medical registries provide a clinical baseline, patient-led platforms offer vital real-world insights. Currently, 107 people with Camurati-Engelmann disease have joined the DiseaseMaps.org community and shared their experiences. This data is invaluable as it helps researchers understand the patient journey beyond the limited scope of published case reports, highlighting the day-to-day impact of the disease and the diagnostic delays that many families face before reaching a specialist.

Next steps

• Consult with a geneticist or a metabolic bone disease specialist to confirm a diagnosis via TGFB1 molecular testing.


• Connect with the 107 members of the DiseaseMaps.org community to share experiences and coping strategies for managing chronic bone pain.


• Request a referral to a center of excellence specializing in skeletal dysplasias to ensure a comprehensive management plan.


• Monitor for updates on clinical research via NIH GARD to stay informed about potential therapeutic advancements.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Camurati-Engelmann disease (ORPHA:280)


• NIH Genetic and Rare Diseases (GARD) Information Center: Progressive diaphyseal dysplasia


• OMIM (Online Mendelian Inheritance in Man): Camurati-Engelmann disease (#131300)


• DiseaseMaps.org: Community insights and patient registry data